Transcriptomics

Dataset Information

0

Cell-autonomous Inflammation of BRCA1-deficient Ovarian Cancers Drives Intrinsic Immunoreactivity and Immune Resistance through STING and VEGF


ABSTRACT: BRCA1 loss leads to tumor cell transcriptional reprogramming, resulting in a DNA damage-driven, mandatory cell-autonomous type I IFN inflammatory activation mediated by STING and TREX1/2. PARP inhibition augmented this immunoreactivity, creating contextual lethality to dual immune checkpoint blockade (ICB) in vivo. BRCA1-deficient tumor can escape T-cell inflammation through targeted deletion or methylation of the DNA sensing/IFN pathway genes, such as STING, IFNB1 or the chemokine CCL5. Alternatively, BRCA-mutated carcinomas retaining immunoreactivity upregulate their VEGF-A expression driven by STING, which mediates immune resistance and tumor progression. STING elimination attenuated tumor growth and abrogated therapeutic resistance to dual ICB. VEGF-A blockade synergized with immune checkpoint blockade and/or PARP inhibition to control outgrowth of Brca1-/- ovarian tumors, offering opportunities for rational combination therapy of cancers with homologous recombination repair deficiency (HRD).

ORGANISM(S): Mus musculus

PROVIDER: GSE162935 | GEO | 2021/06/16

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-01-01 | E-MTAB-12922 | biostudies-arrayexpress
2024-07-09 | GSE237615 | GEO
2021-06-16 | GSE122153 | GEO
2021-06-16 | GSE122154 | GEO
2021-06-16 | GSE120792 | GEO
2023-09-28 | GSE244296 | GEO
2023-11-18 | GSE161922 | GEO
2023-11-18 | GSE161912 | GEO
2023-08-01 | GSE237361 | GEO
2024-01-24 | PXD046384 | Pride